You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Indications

Active ingredients of Incruse Ellipta 1

Incruse Ellipta 55 mcg (umeclidinium) inhalation powder.

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms (mcg) umeclidinium (equivalent to 65 mcg of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 mcg umeclidinium equivalent to 74.2 mcg umeclidinium bromide.

Incruse Ellipta Indication:

Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 1

Reference:

  1. Incruse Ellipta 55 mcg SPC; GlaxoSmithKline 2018

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Incruse Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies